SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to exceptionally high short interest fueling intense short squeeze speculation, amplified by recent global regulatory approvals for its Anktiva cancer treatment. The community is rallying behind Dr. Patrick Soon-Shiong's vision for a potential chemo-free cancer solution, actively discussing the drug's expanding market potential and the increasing pressure on short sellers.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is surging following its Japan PMDA marketing approval for Alpha DaRT and encouraging clinical updates for a second Glioblastoma (GBM) patient. The community is highly bullish, anticipating a significant breakout as institutional interest grows and the company transitions to global commercialization of its physics-based 'universal killer' cancer treatment.

DHT Holdings, Inc. engages in the operation of a fleet of crude oil tankers. It operates through its integrated management companies in Monaco, Singapore, and Oslo, Norway. The company was founded in 2005 and is headquartered in Hamilton, Bermuda.

DHT Holdings Inc

DHT Holdings is trending as a pure-play VLCC tanker company capitalizing on global tariffs and geopolitical tensions that are extending oil shipping routes and tightening vessel supply, leading to skyrocketing charter rates. The community is highly bullish, viewing it as a "dividend monster" with a 100% net income payout policy, expecting significant future payouts.

HP Inc. is an information technology company, which engages in the provision of personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services. It operates through the following segments: Personal Systems, Printing, and Corporate Investments. The Personal Systems segment offers commercial and consumer desktop and notebook personal computers, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, solutions and services, and scanning devices. The Corporate Investments segment includes HP Labs and certain business incubation projects. The company was founded by William R. Hewlett and David Packard in 1939 and is headquartered in Palo Alto, CA.

HP Inc

HPQ is actively trending as its CEO's departure to PayPal compounds investor concern over recent weak guidance and rising memory costs, yet a strong contingent of the community sees deep value in its dividend yield and long-term AI PC potential at current depressed levels.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group (LCID) is trending after its recent earnings report highlighted strong revenue growth but a wider-than-expected operating loss, fueling community debate over the company's significant cash burn and elusive path to profitability. Despite workforce reductions and plans for future vehicle launches, investors are actively discussing ongoing dilution risks and the continued absence of a permanent CEO in a competitive EV landscape.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community discussion explodes following Donald Trump's State of the Union address, with supporters hailing his speech while critics accuse him of delivering a 'clown show' full of lies, alongside renewed chatter around tariffs and ongoing Epstein claims.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is trending after UBS significantly increased its lithium price outlook by 74%, fueling community discussions about an impending lithium deficit and potential short squeeze. This bullish sentiment is further supported by the company's sale of high-purity lithium fines at premium prices, consistent insider buying, and active efforts to counter inaccurate media reports.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors anticipate its upcoming earnings, driven by robust community discussion around the company's pivotal role in surging AI server demand and the broader AI infrastructure buildout. However, sentiment is mixed due to ongoing concerns about PC business weakness and rising memory costs, intensified by analyst downgrades that some market participants view as manipulative.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Record-high short interest is fueling community speculation of an imminent squeeze for RUM, with investors highlighting Tether's increasing ownership and substantial financial commitments for advertising and AI cloud services following the Northern Data acquisition.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as the community keenly watches escalating tensions surrounding a potential conflict with Iran, driving speculation for a significant surge in market volatility. While many traders are positioning for an upside move, a strong counter-narrative highlights the ETF's inherent decay and the historical tendency of volatility spikes to fade quickly.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics drew heavy retail interest on Tuesday after its partner, Akeso, reported that ivonescimab (AK112), a closely watched lung cancer drug, helped patients live longer in a key late-stage trial.Akeso said the final analysis of the Phase III study in patients with EGFR-mutated, advanced non-squamous non-small cell lung cancer who had already failed EGFR-TKI therapy showed ivonescimab extended overall survival, meeting the trial’s main goal with a clear and meaningful benefit.&nbsp;Detailed data will be presented at an upcoming medical conference.The update came alongside Akeso’s first-half earnings and drove its Hong Kong-listed shares up as much as 5.92% on Wednesday. Meanwhile, Summit, which holds U.S. rights to ivonescimab, rose as much as 14% Tuesday on the news.&nbsp;While the drug is already approved in China, Summit is running a similar trial with a broader, global population to pave the way for an approval in the U.S.Ivonescimab has already won two approved indications in China: for EGFR-mutated NSCLC after EGFR-TKI therapy, and as monotherapy for PD-L1-positive advanced NSCLC.&nbsp;The drug has been included in clinical treatment guidelines, and Akeso has launched over 30 trials, including 13 Phase III studies and six head-to-head comparisons with PD-(L)1 therapies.Bernstein analysts led by Rebecca Liang called the survival data “a positive surprise,” noting that whether the drug could extend overall survival “has been the center of debate for AK112 since last year,” Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-27/akeso-s-lung-cancer-drug-hits-key-goal-in-china-study">reported</a>.&nbsp;They added it could be the biggest positive catalyst for Akeso since the company announced ivonescimab had outperformed Merck &amp; Co.’s top-selling cancer drug in a separate trial.On Stocktwits, retail sentiment was ‘extremely bullish’ for Summit Therapeutics amid ‘extremely high’ message volume, while Akeso drew ‘bullish’ sentiment with ‘high’ activity.One user speculated that Summit shares could reach $35 by&nbsp;the end of the week.&nbsp;<stembedurl>https://stocktwits.com/___dog___/message/626653621</stembedurl>Another suggested the stock was still digesting the overall survival news and argued it should already be trading above $30.<stembedurl>https://stocktwits.com/BooEmmy/message/626614344</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 51.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/AKESF">Akeso’s U.S.-listed shares</a> have more than tripled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Equity

Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. It operates through the following geographical segments: Chinese Mainland, USA, and Other Regions. The company was founded by Yu Xia, Peng Zhang, Baiyong Li, and Zhongmin Wang in March 2012 and is headquartered in Zhongshan, China.

Akeso Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$13.58
Prev Close	$14.25
Open	$14.25
Dividend Yield	0.00%
50-Day Moving Average	$14.47
Beta	0.00
Avg. Volume	2,214.50
PE Ratio	-109.03

52-Week High	$23.15
52-Week Low	$8.25
Market Capitalization	$13.11B
EPS (Annual)	-$0.084
Price to Book	14.22
Revenue Per Employee	$97,239.76

AKESF
Akeso Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKESF News

AKESFAkeso Inc